OAM
SGMO

Oxford Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Oxford Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24,247
Closed -$412K – 2068
2018
Q3 		$412K Buy
+24,247
New +$369K 0.01% 1387
2017
Q4 		– Sell
-63,040
Closed -$943K – 1843
2017
Q3 		$943K Buy
+63,040
New +$697K 0.02% 959
2016
Q3 		– Sell
-77,442
Closed -$448K – 851
2016
Q2 		$448K Sell
77,442
-335,702
-81% -$2.14M 0.01% 600
2016
Q1 		$2.5M Sell
413,144
-28,140
-6% -$169K 0.07% 321
2015
Q4 		$4.04M Buy
441,284
+221,120
+100% +$1.7M 0.1% 231
2015
Q3 		$1.24M Buy
220,164
+42,856
+24% +$353K 0.04% 371
2015
Q2 		$1.97M Buy
177,308
+40,616
+30% +$524K 0.05% 349
2015
Q1 		$2.14M Sell
136,692
-92,770
-40% -$1.44M 0.05% 349
2014
Q4 		$3.41M Buy
229,462
+99,035
+76% +$1.2M 0.08% 265
2014
Q3 		$1.41M Buy
+130,427
New +$1.7M 0.03% 425
2013
Q3 		– Sell
-79,432
Closed -$620K – 886
2013
Q2 		$620K Buy
+79,432
New +$693K 0.02% 663

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oxford Asset Management's SGMO Position: Q4 2018 in Review

Oxford Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 24,247 shares — an estimated $412K sold.

Oxford Asset Management first reported a position in SGMO in Q2 2013 and held it in 11 quarters. The position peaked at $4.04M in Q4 2015. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • Oxford Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • Oxford Asset Management sold 24,247 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $412K.
  • Oxford Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 11 quarters.
  • Oxford Asset Management's SANGAMO THERAPEUTICS INC position peaked at $4.04M in Q4 2015.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.